This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Picking up post #58: that is the part I would want checked first.
I disagree with the reply above, and I think the disagreement is substantive rather than terminological.
The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.
Coming back to post #60, because the follow-up matters more than the original answer.
Germany: BfArM implements EU framework. Statutory insurance (the majority) excludes "lifestyle medicines" including weight management. Private prescription is common. Private insurance sometimes covers it.
Reimbursement varies substantially by member state. Some (Germany, France, Netherlands) restrict weight-management coverage. Others are more permissive. That variation is the single most determinative factor in access for most EU residents.
Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available.
I read post #64 twice before replying, because I had assumed the opposite.
EMA is the regulator with national implementation. Licensed incretin analogues are prescription-only across the EU, with some variation in specific approvals by member state.
post #66 is right about the mechanism and I think understates the practical bit.
Netherlands: CBG-MEB implements framework. GPs are first point of contact. Insurance coverage for weight management is conditional on structured lifestyle programme participation.
Spain: AEMPS is the regulator. Public reimbursement for weight management has been limited with regional variation in specialist pathways. Private prescription is common.
Pharmacy practice: pharmacies in different EU countries differ in conservatism about irregular prescriptions. Some will decline a prescription they consider irregular; others will not. Local pharmacy culture matters.
On post #67 — agreed on the reasoning, with one qualification.
France: ANSM implements EU framework. Reimbursement has been narrower for weight management. Prescribing restrictions were applied during shortages, directing available product toward diabetes indications.
post #71 answers the question as asked. The question underneath it is different.
I disagree with the reply above, and I think the disagreement is substantive rather than terminological.
The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.
Germany: BfArM implements EU framework. Statutory insurance (the majority) excludes "lifestyle medicines" including weight management. Private prescription is common. Private insurance sometimes covers it.
Worth separating two things that post #71 runs together.
Spain: AEMPS is the regulator. Public reimbursement for weight management has been limited with regional variation in specialist pathways. Private prescription is common.
Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.
The correction was fair and I had been repeating something I had not checked carefully enough.
Germany: BfArM implements EU framework. Statutory insurance (the majority) excludes "lifestyle medicines" including weight management. Private prescription is common. Private insurance sometimes covers it.
EMA is the regulator with national implementation. Licensed incretin analogues are prescription-only across the EU, with some variation in specific approvals by member state.
post #80 answers the question as asked. The question underneath it is different.
Reimbursement varies substantially by member state. Some (Germany, France, Netherlands) restrict weight-management coverage. Others are more permissive. That variation is the single most determinative factor in access for most EU residents.
Private prescription with self-payment is legal across the EU and is the common route where public reimbursement is not available.
I disagree with the reply above, and I think the disagreement is substantive rather than terminological.
The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.
Coming back to post #82, because the follow-up matters more than the original answer.
Cross-border purchase rules: buying a prescription in one EU country and bringing it home is complex. The substance is legal but crossing borders with it requires understanding both countries' import rules.
Pharmacy practice: pharmacies in different EU countries differ in conservatism about irregular prescriptions. Some will decline a prescription they consider irregular; others will not. Local pharmacy culture matters.
Germany: BfArM implements EU framework. Statutory insurance (the majority) excludes "lifestyle medicines" including weight management. Private prescription is common. Private insurance sometimes covers it.
I read post #86 twice before replying, because I had assumed the opposite.
Two things before anyone answers the substance.
First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.
Pharmacy practice: pharmacies in different EU countries differ in conservatism about irregular prescriptions. Some will decline a prescription they consider irregular; others will not. Local pharmacy culture matters.
Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.